VTGN (Vistagen Therapeutics) Total Stockholders Equity: $35.52 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VTGN Vistagen Therapeutics Inc VTGN
16 GF Score
Price $0.29
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Total Stockholders Equity?

Vistagen Therapeutics VTGN +3.21% 16 Total Stockholders Equity is $35.52 Mil as of Mar. 2026. GuruFocus rates VTGN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review.

Vistagen Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $35.52 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Vistagen Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was $0.90. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Vistagen Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.03.

Vistagen Therapeutics  (NAS:VTGN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Vistagen Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(35.52-0)/39.620
=0.90

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Vistagen Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.795 + 0.249) / 35.52
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Total Stockholders Equity Related Terms

Vistagen Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Total Stockholders Equity Chart

Vistagen Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.72 12.08 114.29 70.39 35.52

Vistagen Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.39 56.77 66.34 50.92 35.52
VTGN
16GF Score
Vistagen Therapeutics Inc VTGN
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $35.52 Mil mean?
Vistagen Therapeutics (VTGN) has a Total Stockholders Equity of $35.52 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vistagen Therapeutics and its competitors.
Is Vistagen Therapeutics' Total Stockholders Equity too high?
Vistagen Therapeutics' current Total Stockholders Equity is $35.52 Mil. Overall, Vistagen Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Total Stockholders Equity compare to ASBP and CRIS?
Vistagen Therapeutics' Total Stockholders Equity of $35.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current Total Stockholders Equity is $35.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (VTGN) has a current Total Stockholders Equity of $35.52 Mil. The current Total Stockholders Equity is $35.52 Mil. Vistagen Therapeutics' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current Total Stockholders Equity is $35.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vistagen Therapeutics Business Description

Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
16GF Score

Get the complete analysis for VTGN

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.29
Price